Weight Watchers Partners with PVOLVE to Deliver Clinically Validated Strength Workouts to Members in the GLP-1 Era

The new partnership combines Weight Watchers' scientifically-backed medical and behavioral expertise with PVOLVE's clinically-studied method to support members at every age and stage of life The new partnership combines Weight Watchers' scientifically-backed medical and behavioral expertise with PVOLVE's clinically-studied method to support members at every age and stage of life

GlobeNewsWire • Feb 10, 2026

Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy® Pill Advancing a New Standard for Long-Term Weight Health

A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone

GlobeNewsWire • Jan 5, 2026

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last

GlobeNewsWire • Dec 16, 2025

WW International: First Normal Quarter Shows Signs Of Stability

WW International (WW) delivered a strong Q3, exceeding revenue and EBITDA expectations, driven by its Clinical Business. WW faces ongoing challenges, including declining Behavioral subscribers and cautious Q4 guidance, which may keep investors wary until trends improve. Key catalysts ahead include FDA decisions on GLP-1 compounding, expanded insurance coverage, and new partnerships with pharma and insurance providers.

Seeking Alpha • Nov 18, 2025

WeightWatchers to sell Novo Nordisk's Wegovy pill after 2026 launch

WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.

Reuters • Nov 12, 2025

WeightWatchers Announces Third Quarter 2025 Results

End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand  Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net Loss Margin of 33.4%; Adjusted EBITDA 1 of $43 million and Adjusted EBITDA Margin 1 of 24.9% Narrowing 2025 Guidance to the higher end of previous ranges for Revenue and Adjusted EBITDA1 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the third quarter of fiscal 2025 ended September 30, 2025 2 in this Earnings Press Release and a Shareholder Letter posted on the Company's Corporate Website . Third Quarter 2025 Overview Q3 reflected a significantly strengthened balance sheet as the Company's first full quarter post-restructuring, with total debt reduced by more than 70% (~$1.1 billion) and Cash at quarter end increasing to $170 million from $152 million at the end of Q2.

GlobeNewsWire • Nov 6, 2025

WW International, Inc. (WW) Q3 2025 Earnings Call Transcript

WW International, Inc. ( WW ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants David Helderman - Director of Investor Relations Tara Comonte - President, CEO & Director Felicia DellaFortuna - Chief Financial Officer Jon Volkmann - Chief Operations Officer Conference Call Participants Alex Fuhrman - Lucid Capital Markets, LLC, Research Division Justin Ages - CJS Securities, Inc. Nathaniel Feather - Morgan Stanley, Research Division Presentation Operator Good morning, and welcome to WeightWatchers International's Third Quarter 2025 Results Conference Call. [Operator Instructions] Please note this event is being recorded.

Seeking Alpha • Nov 6, 2025

Why WW International Skyrocketed by 9% on Monday

WW International (WGHW 9.25%), owned of the storied Weight Watchers diet system, wasn't slimming down on Monday -- at least as far as its equity was concerned. The company's share price zoomed over 9% higher on the day, thanks in no small part to a deal it announced with a major e-commerce enterprise.

The Motley Fool • Oct 20, 2025

WeightWatchers International shares climb after partnership with Amazon Pharmacy

Shares of WW International rose nearly 6% in premarket trading on Monday after the company announced a new partnership with Amazon to deliver GLP-1 weight-loss drugs and other prescription medications directly to its members.

Invezz • Oct 20, 2025

WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a collaboration with Amazon Pharmacy , a full-service online pharmacy. Through this collaboration, WeightWatchers Clinic members will gain access to real-time medication availability, automatic coupon savings, and fast, reliable home delivery for weight management medications.

GlobeNewsWire • Oct 20, 2025